Skip to main content

Table 3 Description of therapies prior to randomization, monitoring during aerosol administration, and outcomes of enrolled infants

From: Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials

Case number Before study aerosol During study aerosol After study aerosol
Surfactant Inotropes Pulmonary vasodilators Ventilator Mode Maximum Temperature (°C) Maximum HR (bpm) Minimum MBP (mmHg) Duration of study aerosol (hours) Was ECMO provided? Time to ECMO (hours)c Neuroimaging at discharge
Control group:
2 Yes Dopamine Milrinone Sildenafil CMV 38.0 177 37 31.1 Yes 1.5 Normal study
4 Yes Dopamine Milrinone HFO 37.5 185 32 72 No   Bilateral cephalhematomas, thinning corpus callosum
5 No Dopamine Dobutamine - HFO 38.2 200 47 44.9 Yes 24.2 diffuse abnormality, white matter signal ↑ on T2 weighted MRI
Low-dose IPGE1 group:
3 Yes Dopamine Dobutamine - HFO 33.6 131 46 10.1 Yes 1.5 Normal study
6 No - Milrinone HFO 30.6 118 43 36 Yes Not knowna Unknown
High-dose IPGE1 group:
1 Yes Dopamine Dobutamine - HFO 33.5 142 45 39.5 Yes 1.2 ↑ lactate peak suggestive of HIE
7b Yes Dopamine - CMV 33.7 121 63 34 Yes 4 Grade II IVH and posterior fossa hemorrhage
  1. CMV, conventional mechanical ventilation; HFO, high frequency oscillator.; HIE, hypoxic ischemic encephalopathy; IVH, intraventricular hemorrhage; MRI, magnetic resonance imaging; ↑, increased.
  2. aInfant received ECMO at another institution, time of ECMO not known.
  3. bInfant received low-dose IPGE1 for first 24 hours though randomized to high-dose IPGE1; thereafter switched to low-dose IPGE1.
  4. cTime from stop of study aerosol to initiation of ECMO (hours).